Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263102 | 0.89 | TSHR (0.46) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL28300921 | 0.85 | TSHR (0.53) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL2381586 | 0.82 | TSHR (0.54) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL2598195 | 0.81 | TDP1 (0.49) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL5314234 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL1355836 | 0.80 | TSHR (0.51) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL29561089 | 0.80 | TSHR (0.51) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL17688824 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL2084778 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL1644833 | 0.79 | ALDH1A1 (0.47) | ALDH1A1TDP1TSHRCYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-28 | — | — | US | disclosed |
| EP-2595482-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP11B2, HSD11B2 | ALDH1A1 300/4885TDP1 3119/4885TSHR 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.